Rhythm Pharmaceuticals, Inc.
RYTM
Updated: 23/09/2026, 15:26:46
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
No summaries found.
- Share price
- $99.27
- Market cap
- $6.81B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- David Meeker
- Employees
- 414
- IPO date
- 09/10/2017
- Beta
- 1.968
- Last dividend
- $0.00
- Day range
- $98.69 – $101.85
- 52-week range
- $74.50 – $122.20
- 1-day performance
- 0.45%
- 1-year performance
- 33.25%
- Current drawdown (1Y)
- -18.76%
- CIK
- 0001649904
- CUSIP
- 76243J105
- ISIN
- US76243J1051
- Created
- 07/12/2025, 14:05:50
- Last update
- 23/09/2026, 15:26:46
Track Rhythm Pharmaceuticals, Inc. with an AI analyst
See which prediction-market events move RYTM, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
GlobeNewsWire • STOCK • 12/06/2026, 18:01:00
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 08/06/2026, 19:28:31
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 14/05/2026, 01:00:45
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
GlobeNewsWire • STOCK • 12/05/2026, 10:00:00
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 05/05/2026, 19:31:20
Rhythm Pharmaceuticals Announces Changes to Board of Directors
GlobeNewsWire • STOCK • 03/04/2026, 11:00:00
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength?
Zacks Investment Research • STOCK • 01/04/2026, 11:10:28
PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)
PRNewsWire • STOCK • 20/03/2026, 13:58:00
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity Transcript
Seeking Alpha • STOCK • 20/03/2026, 04:32:19
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Topline Results and Insights from Phase 3 EMANATE Trial Transcript
Seeking Alpha • STOCK • 17/03/2026, 03:02:17
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
GlobeNewsWire • STOCK • 16/03/2026, 17:01:00
Rhythm Pharmaceuticals Q4 Beat Sets Stage For March 20th PDUFA Decision
Seeking Alpha • STOCK • 16/03/2026, 08:30:36